267 related articles for article (PubMed ID: 27716465)
21. Biochemical and genetic characterization of dengue virus methyltransferase.
Dong H; Chang DC; Xie X; Toh YX; Chung KY; Zou G; Lescar J; Lim SP; Shi PY
Virology; 2010 Sep; 405(2):568-78. PubMed ID: 20655081
[TBL] [Abstract][Full Text] [Related]
22. Decreased accumulation of subgenomic RNA in human cells infected with vaccine candidate DEN4Δ30 increases viral susceptibility to type I interferon.
Bustos-Arriaga J; Gromowski GD; Tsetsarkin KA; Firestone CY; Castro-Jiménez T; Pletnev AG; Cedillo-Barrón L; Whitehead SS
Vaccine; 2018 Jun; 36(24):3460-3467. PubMed ID: 29752023
[TBL] [Abstract][Full Text] [Related]
23. Identification of the critical linker residues conferring differences in the compactness of NS5 from Dengue virus serotype 4 and NS5 from Dengue virus serotypes 1-3.
Subramanian Manimekalai MS; Saw WG; Pan A; Grüber A; Grüber G
Acta Crystallogr D Struct Biol; 2016 Jun; 72(Pt 6):795-807. PubMed ID: 27303800
[TBL] [Abstract][Full Text] [Related]
24. Revisiting dengue virus-host cell interaction: new insights into molecular and cellular virology.
Acosta EG; Kumar A; Bartenschlager R
Adv Virus Res; 2014; 88():1-109. PubMed ID: 24373310
[TBL] [Abstract][Full Text] [Related]
25. Immune responses to dengue virus in the skin.
Rathore APS; St John AL
Open Biol; 2018 Aug; 8(8):. PubMed ID: 30135238
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.
Grifoni A; Angelo M; Sidney J; Paul S; Peters B; de Silva AD; Phillips E; Mallal S; Diehl SA; Botten J; Boyson J; Kirkpatrick BD; Whitehead SS; Durbin AP; Sette A; Weiskopf D
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148797
[TBL] [Abstract][Full Text] [Related]
27. Development of specific dengue virus 2'-O- and N7-methyltransferase assays for antiviral drug screening.
Barral K; Sallamand C; Petzold C; Coutard B; Collet A; Thillier Y; Zimmermann J; Vasseur JJ; Canard B; Rohayem J; Debart F; Decroly E
Antiviral Res; 2013 Sep; 99(3):292-300. PubMed ID: 23769894
[TBL] [Abstract][Full Text] [Related]
28. Dengue Virus Control of Type I IFN Responses: A History of Manipulation and Control.
Castillo Ramirez JA; Urcuqui-Inchima S
J Interferon Cytokine Res; 2015 Jun; 35(6):421-30. PubMed ID: 25629430
[TBL] [Abstract][Full Text] [Related]
29. Dengue virus NS2B protein targets cGAS for degradation and prevents mitochondrial DNA sensing during infection.
Aguirre S; Luthra P; Sanchez-Aparicio MT; Maestre AM; Patel J; Lamothe F; Fredericks AC; Tripathi S; Zhu T; Pintado-Silva J; Webb LG; Bernal-Rubio D; Solovyov A; Greenbaum B; Simon V; Basler CF; Mulder LC; García-Sastre A; Fernandez-Sesma A
Nat Microbiol; 2017 Mar; 2():17037. PubMed ID: 28346446
[TBL] [Abstract][Full Text] [Related]
30. Experimental in vitro and in vivo systems for studying the innate immune response during dengue virus infections.
Kitab B; Kohara M; Tsukiyama-Kohara K
Arch Virol; 2018 Jul; 163(7):1717-1726. PubMed ID: 29520688
[TBL] [Abstract][Full Text] [Related]
31. Innate and adaptive immune evasion by dengue virus.
Lee MF; Voon GZ; Lim HX; Chua ML; Poh CL
Front Cell Infect Microbiol; 2022; 12():1004608. PubMed ID: 36189361
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies.
Ubol S; Phuklia W; Kalayanarooj S; Modhiran N
J Infect Dis; 2010 Mar; 201(6):923-35. PubMed ID: 20158392
[TBL] [Abstract][Full Text] [Related]
33. The Transactions of NS3 and NS5 in Flaviviral RNA Replication.
Tay MYF; Vasudevan SG
Adv Exp Med Biol; 2018; 1062():147-163. PubMed ID: 29845531
[TBL] [Abstract][Full Text] [Related]
34. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness.
Manokaran G; Finol E; Wang C; Gunaratne J; Bahl J; Ong EZ; Tan HC; Sessions OM; Ward AM; Gubler DJ; Harris E; Garcia-Blanco MA; Ooi EE
Science; 2015 Oct; 350(6257):217-21. PubMed ID: 26138103
[TBL] [Abstract][Full Text] [Related]
35. Co-circulation of dengue virus serotypes in Central India: Evidence of prolonged viremia in DENV-2.
Agarwal A; Gupta S; Chincholkar T; Singh V; Umare IK; Ansari K; Paliya S; Yadav AK; Chowdhary R; Purwar S; Biswas D
Infect Genet Evol; 2019 Jun; 70():72-79. PubMed ID: 30798036
[TBL] [Abstract][Full Text] [Related]
36. Antibody-dependent enhancement of dengue virus infection inhibits RLR-mediated Type-I IFN-independent signalling through upregulation of cellular autophagy.
Huang X; Yue Y; Li D; Zhao Y; Qiu L; Chen J; Pan Y; Xi J; Wang X; Sun Q; Li Q
Sci Rep; 2016 Feb; 6():22303. PubMed ID: 26923481
[TBL] [Abstract][Full Text] [Related]
37. Immune response to dengue virus and prospects for a vaccine.
Murphy BR; Whitehead SS
Annu Rev Immunol; 2011; 29():587-619. PubMed ID: 21219187
[TBL] [Abstract][Full Text] [Related]
38. Characterization of RyDEN (C19orf66) as an Interferon-Stimulated Cellular Inhibitor against Dengue Virus Replication.
Suzuki Y; Chin WX; Han Q; Ichiyama K; Lee CH; Eyo ZW; Ebina H; Takahashi H; Takahashi C; Tan BH; Hishiki T; Ohba K; Matsuyama T; Koyanagi Y; Tan YJ; Sawasaki T; Chu JJ; Vasudevan SG; Sano K; Yamamoto N
PLoS Pathog; 2016 Jan; 12(1):e1005357. PubMed ID: 26735137
[TBL] [Abstract][Full Text] [Related]
39. The Molecular Specificity of the Human Antibody Response to Dengue Virus Infections.
Gallichotte EN; Baric RS; de Silva AM
Adv Exp Med Biol; 2018; 1062():63-76. PubMed ID: 29845525
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complex.
Rodriguez-Madoz JR; Belicha-Villanueva A; Bernal-Rubio D; Ashour J; Ayllon J; Fernandez-Sesma A
J Virol; 2010 Oct; 84(19):9760-74. PubMed ID: 20660196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
